Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221773 | 0.81 | HSD17B10 (0.54) | GPR35TNFRSF1AKDM4EMEN1KMT2A | |
| SCHEMBL6225634 | 0.81 | TNFRSF1A (0.43) | TNFRSF1AKDM4EMEN1KMT2AATM | |
| SCHEMBL699964 | 0.80 | CCR2 (0.65) | GPR35KDM4ECCR2MEN1KMT2A | |
| SCHEMBL4209306 | 0.77 | CCR9 (0.56) | CCR2MEN1KMT2ACCR9RHEB | |
| SCHEMBL6303493 | 0.77 | CCR2 (0.62) | CCR2CCR9MAPTRHEB | |
| SCHEMBL7079495 | 0.77 | CCR2 (0.47) | CCR2CCR9MAPTRHEBTP53 | |
| SCHEMBL6300529 | 0.76 | CCR2 (0.49) | CCR2POLBCCR9MAPTRHEB | |
| SCHEMBL6300706 | 0.76 | CCR9 (0.53) | KDM4ECCR2CCR9NPSR1RHEB | |
| SCHEMBL699823 | 0.76 | KDM4E (0.47) | GPR35KDM4ECCR2MEN1KMT2A | |
| SCHEMBL18247515 | 0.75 | CCR2 (0.64) | GPR35KDM4ECCR2POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068858-B1 | Use of 4,6-dimethoxyindole-2-carboxylic acid for stimulating or inducing hair growth and/or arresting hair loss | OREAL (FR) | 2005-04-13 | — | — | EP | claimed |
| EP-1068865-B1 | Use of 4,6-dimethoxy-indole 2-carboxylic acid or derivatives thereof for seborrhea treatment | OREAL (FR) | 2005-03-16 | — | — | EP | claimed |
| US-6541507-B1 | Notably 4,6-dimethoxyindole-2-carboxylic acid and derivatives thereof | SOCIETE L'OREAL S.A. (FR) | 2003-04-01 | — | — | US | claimed |
| US-20020058680-A1 | Indolecarboxylic compounds for treating seborrhea and complications thereof | DALKO MARIA (FR) | 2002-05-16 | — | — | US | claimed |
| US-6335359-B1 | TOPICALLY APPLYING TO SKIN OR SCALP TO TREAT DERMATITIS OR ACNE; SIDE EFFECT REDUCTION | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | claimed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2367817-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-6548532-B2 | Topically applying onto the afflicted skin and/or scalp cosmetically/ therapeutically effective amount of indolecarboxylic acid compound, or ester or salt thereof | SOCIETE L'OREAL S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-6541507-B1 | Notably 4,6-dimethoxyindole-2-carboxylic acid and derivatives thereof | SOCIETE L'OREAL S.A. (FR) | 2003-04-01 | — | — | US | disclosed |
| US-20020058680-A1 | Indolecarboxylic compounds for treating seborrhea and complications thereof | DALKO MARIA (FR) | 2002-05-16 | — | — | US | disclosed |
| US-6335359-B1 | TOPICALLY APPLYING TO SKIN OR SCALP TO TREAT DERMATITIS OR ACNE; SIDE EFFECT REDUCTION | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | GPR35 1008/4885TNFRSF1A 4264/4885KDM4E 2709/4885 |
| US-20020058680-A1 | Indolecarboxylic compounds for treating seborrhea and complications thereof | AADAT, CUTA, ALOX15B | GPR35 704/4885TNFRSF1A 949/4885KDM4E 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.